title: High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.
abstract: Adjuvant chemotherapy is commonly given to surgically treated non-small-cell lung cancer (NSCLC) patients. However, the prerequisite for chemotherapy needs to be scrutinized in order to maximize the benefits to patients. In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin. In addition, paclitaxel and cisplatin caused Id1 protein degradation through ubiquitination. In the nude mice xenograft model, the tumor growth was reduced to a large degree in the Id1-overexpressing group upon treatment with paclitaxel and cisplatin. Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy. In summary, our current data suggest that Id1, a generally negative prognostic factor, predicts a favorable prognosis in the case of surgically treated NSCLC patients receiving the definitive adjuvant chemotherapy. The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin.
authors.affiliation: Division of Thoracic Surgery, Department of Surgery, and Cancer Center, E-DA Hospital, Kaohsiung, Taiwan. Department of Postgraduate Medicine, School of Medicine for International Student, I-Shou University, Kaohsiung, Taiwan.
authors.forename: Yu-Jen
authors.initials: YJ
authors.lastname: Cheng
authors.affiliation: Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Yi-Chen
authors.initials: YC
authors.lastname: Lee
authors.affiliation: Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Wen-Chin
authors.initials: WC
authors.lastname: Chiu
authors.affiliation: Department of Anatomic Pathology, E-DA Hospital, Kaohsiung, Taiwan.
authors.forename: Jen-Wei
authors.initials: JW
authors.lastname: Tsai
authors.affiliation: Translational Research Center, Department of Medical Research, and Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Yu-Han
authors.initials: YH
authors.lastname: Su
authors.affiliation: Translational Research Center, Department of Medical Research, and Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Amos C
authors.initials: AC
authors.lastname: Hung
authors.affiliation: Division of General Surgery, Department of Surgery, E-DA Hospital, Kaohsiung, Taiwan.
authors.forename: Po-Chih
authors.initials: PC
authors.lastname: Chang
authors.affiliation: Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Chih-Jen
authors.initials: CJ
authors.lastname: Huang
authors.affiliation: Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Chee-Yin
authors.initials: CY
authors.lastname: Chai
authors.affiliation: Translational Research Center, Department of Medical Research, and Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Shyng-Shiou F
authors.initials: SS
authors.lastname: Yuan
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D045744:Cell Line, Tumor; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D051798:Inhibitor of Differentiation Protein 1 / Q000378:metabolism*; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011379:Prognosis; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry; D016896:Treatment Outcome; D025801:Ubiquitin / Q000737:chemistry
chemical_list: C497453:ID1 protein, human; D051798:Inhibitor of Differentiation Protein 1; D025801:Ubiquitin; D046988:Proteasome Endopeptidase Complex; D017239:Paclitaxel; D002945:Cisplatin